Darzalex Drives J&J’s Revenue Growth

Darzalex Continues Rising Trend – J&J Boosts Projected Yearly Revenues by $1 Billion

In 2017, Genmab CEO Jan van de Winkel envisioned that the multiple myeloma drug Darzalex, marketed by Johnson & Johnson, ...